Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-035 in relapsed/refractory chronic lymphocytic leukemia and hematological malignancies
NCT05944978Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Multispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GNC-035 in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 3 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
GNC-035
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05944978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05944978.